# US 2012/0252731 A1 · Co-Administration of An Agent Linked to an Internalization Peptide With an Anti-Inflammatory

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252731 A1
- Document ID: US20120252731A1
- Status: Published application
- Kind: A1
- Application number: 13/377,519
- Filed: 2010-06-10
- Published: 2012-10-04
- Earliest claimed: 2009-06-10
- Assignees: NoNO Inc.
- Inventors: Michael Tymianksi; Jonathan David Garman
- Web page: https://patentgrep.com/patent/US20120252731A1

## CPC

- A61K 31/275: Nitriles; Isonitriles
- A61K 31/277: having a ring, e.g. verapamil
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 47/645: {Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/1147: {Regulatory proteins, e.g. trans-activator of transcription [TAT], rev or vacuolar protein targeting [VPT]}
- C07K 2319/10: containing a tag for extracellular membrane crossing, e.g. TAT or VP22
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention provides methods of delivering pharmacologic agents linked to an internalization peptide, in which an inflammatory response inducible by the internalization peptide is inhibited by co-administration of an anti-inflammatory or by linking the internalization peptide to biotin or similar molecule. Such methods are premised in part on the results described in the examples whereby administration of a pharmacological agent linked to tat at high dosages is closely followed by an inflammatory response, which includes mast cell degranulation, histamine release and the typical sequelae of histamine release, such as redness, heat, swelling, and hypotension.

## Claims

### Claim 1

A method of inhibiting cerebral ischemia due to endovascular surgery, comprising:
administering to a subject undergoing endovascular surgery a pharmacologic agent that inhibits binding of PSD95 to NDMAR 2B linked to an internalization peptide in a regime effective to inhibit cerebral ischemia; and
administering to the subject a mast cell degranulation inhibitor, whereby the mast cell degranulation inhibitor can inhibit an-anti-inflammatory response inducible by the internalization peptide and/or the mast cell degranulation inhibitor is administered within a period of 30 minutes before to 15 minutes after the pharmacological agent.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The method of claim 1, wherein the mast cell degranulation inhibitor is administered at the same time as or up to 15 minutes before the pharmacological agent.

### Claim 4 (depends on 1, 2, 3)

The method of claim 1, 2 or 3, wherein the mast cell degranulation inhibitor is co-formulated with the pharmacologic agent.

### Claim 5 (depends on 1)

The method of claim 1, wherein the mast cell degranulation inhibitor is administered by a peripheral route.

### Claim 6 (depends on 1)

The method of claim 1, wherein the mast cell degranulation inhibitor and pharmacologic agent are administered intravenously.

### Claim 7 (depends on 1)

The method of claim 1, wherein the subject is suffering from an episode of a disease and the pharmacological agent and the mast cell degranulation inhibitor are administered once during the disease episode.

### Claim 8 (depends on 1)

The method of claim 1, wherein the administration of the mast cell degranulation inhibitor does not comport with a recurring regime of administering the mast cell degranulation inhibitor to the patient without the pharmacologic agent.

### Claim 9 (depends on 1)

The method of claim 1, wherein the internalization peptide is a tat peptide.

### Claim 10 (depends on 9)

The method of claim 9, wherein the tat peptide has an amino acid sequence comprising RKKRRQRRR (SEQ ID NO:51) or GRKKRRQRRR (SEQ ID NO:1).

### Claim 11 (depends on 10)

The method of claim 10, wherein the tat peptide has an amino acid sequence comprising YGRKKRRQRRR (SEQ ID NO:2).

### Claim 12 (depends on 10)

The method of claim 10 wherein the tat peptide has an amino acid sequence comprising of FGRKKRRQRRR (SEQ ID NO:3).

### Claim 13 (depends on 10)

The method of claim 10, wherein the tat peptide has an amino acid sequence comprising GRKKRRQRRRP (SEQ ID NO:4).

### Claim 14 (depends on 1)

The method of claim 1, wherein the pharmacologic agent is a peptide.

### Claim 15 (depends on 1)

The method of claim 1, wherein the pharmacologic agent is KLSSIESDV (SEQ ID NO:5).

### Claim 16

A method of treating or effecting prophylaxis of a disease mediated by excitotoxicity comprising
administering to a subject having or at risk of the disease and effective regime of a peptide having an amino acid sequence consisting of or comprising (RRRQRRKKRGYKLSSIESDV SEQ ID NO:70) to treat or effect prophylaxis of the disease.

### Claim 17 (depends on 16)

The method of claim 16 further comprising administering a mast cell degranulation inhibitor and/or an anti-histamine.

### Claim 18

A peptide having an amino acid sequence consisting of or comprising (RRRQRRKKRGYKLSSIESDV SEQ ID NO:70), optionally formulated with a physiologically acceptable carrier as a pharmaceutical composition.

### Claim 19

A method of delivering a pharmacologic agent to a subject, the method comprising:
administering the pharmacologic agent linked to an internalization peptide to the subject; and
administering an anti-inflammatory agent to the subject, whereby the anti-inflammatory agent can inhibit an inflammatory response from mast cell degranulation inducible by the internalization peptide.

### Claim 20 (depends on 48)

The method of claim 48, wherein the mast cell degranulation inhibitor is administered at the same time as or up to 15 minutes before the pharmacological agent.

### Claim 21 (depends on 48)

The method of claim 48, wherein the mast cell degranulation inhibitor is co-formulated with the pharmacologic agent.

### Claim 22 (depends on 48)

The method of claim 48, for treating or prophylaxis of a disease mediated by excitotoxicity in the subject.

### Claim 23 (depends on 22)

The method of claim 22, wherein the pharmacological agent is PL peptide of an NMDAR receptor.

### Claim 24 (depends on 23)

The method of claim 23, wherein the internalization peptide is a tat peptide.

### Claim 25 (depends on 24)

The method of claim 24, wherein the internalization peptide has an amino acid sequence comprising RKKRRQRRR (SEQ ID NO:51), GRKKRRQRRR (SEQ ID NO:1), YGRKKRRQRRR (SEQ ID NO:2), FGRKKRRQRRR (SEQ ID NO:3) or GRKKRRQRRRPQ (SEQ ID NO:4) or RRRQRRKKRGY (amino acids 1-11 of SEQ ID NO:70).

### Claim 26 (depends on 22)

The method of claim 22, wherein the disease is stroke.

### Claim 27 (depends on 22)

The method of claim 22, wherein the subject is at risk of transient cerebral ischemic attack as a result of undergoing surgery.

### Claim 28 (depends on 19)

The method of claim 19, wherein the mast cell degranulation inhibitor is administered by a peripheral route.

### Claim 29 (depends on 19)

The method of claim 19, wherein the mast cell degranulation inhibitor is administered within a window of 30 minutes before to 15 after administering the pharmacologic agent.

### Claim 30 (depends on 19)

The method of claim 19, wherein the mast cell degranulation inhibitor is administered within a window of 15 minutes before to the same time as administering the pharmacologic agent.

### Claim 31 (depends on 28)

The method of claim 28, wherein the subject is suffering from an episode of a disease and the pharmacological agent and the mast cell degranulation inhibitor are administered once during the disease episode.

### Claim 32 (depends on 28)

The method of claim 28, wherein the administration of the mast cell degranulation inhibitor does not comport with a recurring regime of administering the mast cell degranulation inhibitor to the patient without the pharmacologic agent.

### Claim 33 (depends on 19)

The method of claim 19, wherein the mast cell degranulation inhibitor and pharmacological agent linked to the internalization peptide are co-formulated.

### Claim 34 (depends on 33)

The method of claim 33, wherein the co-formulation is administered intravenously.

### Claim 35

A kit comprising a pharmacological agent linked to an internalization peptide, and lodoxamide.

### Claim at position 36

36-39. (canceled)

### Claim 40

A co-formulation comprising lodoxamide and a peptide having an amino acid sequence of SEQ ID NO:6 (YGRKKRRQRRRKLSSIESDV) and water.

### Claim 41 (depends on 40)

The co-formulation of claim 40 in which less than 5% by weight of the lodoxamide and less than 5% by weight of the peptide is in particulate form.

### Claim 42 (depends on 40)

The co-formulation composition of claim 40 further comprising sodium chloride at a concentration of 50-200 mM.

### Claim 43 (depends on 40)

The co-formulation of claim 40, wherein the concentration of lodoxamide is 0.5-1 mg/ml and the concentration of the peptide is 5-20 mg/ml

### Claim 44

A method of delivering a pharmacological agent linked to an internalization peptide to a population of subjects having or a risk of a disease treatable by the pharmacological agent, comprising
administering the pharmacological agent linked to the internalization peptide to the subjects,
wherein some subjects are administered a mast cell degranulation inhibitor to reduce an inflammatory response inducible by the internalization peptide and some subjects are not depending on the dose of the pharmacological agent linked to the internalization peptide with patients receiving a higher dose receiving the mast cell degranulation inhibitor.

### Claim 45

A method of treating or effecting prophylaxis of a disease mediated by excitotoxicity comprising
administering to a human subject having or at risk of the disease a peptide having an amino acid sequence of SEQ ID NO:6 (YGRKKRRQRRRKLSSIESDV) at a dose of greater or equal to 2.0 mg/kg; and
administering to the subject a mast cell degranulation inhibitor, whereby the mast cell degranulation inhibitor can inhibit mast cell degranulation inducible by the internalization peptide and/or the mast cell degranulation inhibitor is administered within a period of 30 minutes before to 15 minutes after the pharmacological agent.

### Claim 46 (depends on 45)

The method of claim 45, wherein the dose is 2.6 mg/kg.

### Claim 47

A method of delivering a pharmacological agent linked to an internalization peptide to a subject having or a risk of a disease treatable by the pharmacological agent, comprising
administering the pharmacological agent linked to the internalization peptide to the subject, administering a mast cell degranulation inhibitor and an anti-histamine to reduce an inflammatory response inducible by the internalization peptide.

### Claim 48 (depends on 19)

The method of claim 19, wherein the anti-inflammatory agent is a mast cell degranulation inhibitor.

### Claim 49 (depends on 48)

The method of claim 48, wherein the mast cell degranulation inhibitor is tranilast, lodoxamide, azelastine, bepotastine, chlorzoxazone, epinastine, isoproterenol, olopatadine, pemirolast, pimecrolimus or pirbuterol.
